Next-Generation Sequencing in Translational Sarcoma Research: Biological Insights and Emerging Directions Authors: Alessandro De Vita, Sara Violani, Giacomo Miserocchi, Elena Xerxa, Jürgen Bajorath, Silvia Vanni Published: 2026 ABSTRACT AbstractPurpose of ReviewSarcomas are rare and heterogeneous malignancies for which molecular diagnostics increasingly complement histopathology, immunohistochemistry, FISH, and RT-PCR. This review summarizes the main research applications of next-generation sequencing (NGS) in sarcoma, with particular attention to mutation and variant discovery, fusion detection, biomarker development, assay validation, multi-omics integration, and the boundaries between exploratory research and clinical implementation.Recent FindingsNGS-based approaches have expanded the detection of recurrent and rare alterations across sarcoma subtypes, including subtype-defining fusions, copy-number changes, actionable kinase rearrangements, and alterations in tumor suppressor and cell-cycle pathways. However, the clinical utility of NGS remains context-dependent and should be interpreted according to tumor subtype, sample quality, available orthogonal methods, multidisciplinary expertise, and current precision-oncology recommendations.SummaryNGS is a powerful tool in translational sarcoma research and, in selected clinical scenarios, supports diagnosis, molecular classification, and therapeutic decision-making. Its use should be presented with appropriate caution, acknowledging technical limitations, the need for expert reference-center interpretation, and the complementary role of established diagnostic techniques.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s11912-026-01828-w.Keywords: Next-generation sequencing, Sarcoma, Mutation discovery, Fusion genes, Biomarkers, Tumor heterogeneity, Precision oncology Introduction Sarcomas are a diverse group of malignant tumors arising from mesenchymal tissues, encompassing over 70 histological subtypes that affect bone, cartilage, muscle, and connective tissue [23, 30, 72]. Their rarity and heterogeneity have historically limited research progress, making them some of the most challenging malignancies to study and treat. Traditional diagnostic modalities, such as fluorescence in situ hybridization (FISH) and reverse-transcription polymerase chain reaction (RT-PCR), have contributed substantially to the identification of specific chromosomal translocations and fusion genes in sarcomas, including EWSR1-FLI1/EWSR1-ERG in Ewing sarcoma, SS18-SSX1/2/4 in synovial sarcoma, FUS-DDIT3 in myxoid liposarcoma, COL1A1-PDGFB in dermatofibrosarcoma protuberans, and NAB2-STAT6 in solitary fibrous tumor, PAX3-FOXO1 in alveolar rhabdomyosarcoma [18, 60, 69]. Nevertheless, these techniques are generally most informative when a specific diagnostic hypothesis is already present and when the expected gene partner or breakpoint can be targeted; they may be less efficient for rare, cryptic, or novel rearrangements and for broad molecular characterization [45, 60]. The introduction of next-generation sequencing (NGS) technologies has revolutionized the study of sarcomas by enabling parallel, high-throughput sequencing of DNA and RNA, offering an unbiased view of the genomic landscape [17, 56]. Through whole-genome, whole-exome, and targeted sequencing, NGS has uncovered mutations, gene fusions, copy number variations, and epigenetic alterations that define sarcoma pathogenesis [2, 4]. Beyond mutation discovery, NGS has empowered researchers to explore the transcriptional dynamics, tumor heterogeneity, and molecular evolution of sarcomas [24, 29]. This review summarizes the applications of NGS in translational sarcoma research, spanning mutation discovery, fusion identification, biomarker and assay development, and the incorporation of computational and multi-omics approaches. It also discusses current limitations, the complementary role of conventional molecular techniques, and the importance of expert interpretation in reference centers when NGS is used in exploratory or clinically oriented settings. Mutation and Variant Discovery Mutation discovery remains one of the most significant contributions of NGS to sarcoma research (Table 1). Early genomic studies identified recurrent mutations in tumor suppressor genes such as TP53, RB1, and CDKN2A/B, and in signaling pathways such as PI3K/PTEN/mTOR, which are frequently altered in soft-tissue and bone sarcomas [16, 30]. Nacev et al., [54] demonstrated through large-scale clinical sequencing that sarcomas possess distinct mutational landscapes that vary substantially among subtypes, from translocation-driven tumors like synovial sarcoma to complex karyotype sarcomas such as undifferentiated pleomorphic sarcoma. Recent advances in targeted comprehensive genomic profiling have expanded the catalog of actionable mutations. Bhonde et al., [7] reported novel single-nucleotide variants (SNVs) in rare sarcoma subtypes, while Bajpai et al., [4] linked cellular proliferation and tumor suppression pathways to aggressive disease phenotypes. These discoveries underscore how NGS can uncover both common and subtype-specific driver mutations. Table 1Most relevant mutations and genomic alterations identified by NGS in sarcomas. Abbreviations: DDLPS, dedifferentiated liposarcoma; DFSP, dermatofibrosarcoma protuberans; EWS, Ewing sarcoma; IMT, inflammatory myofibroblastic tumor; LMS, leiomyosarcoma; LOF, loss-of-function; LPS, liposarcoma; MLPS, myxoid liposarcoma; MPNST, malignant peripheral nerve sheath tumor; PEComa, perivascular epithelioid cell tumor; RMS, rhabdomyosarcoma; UPS, undifferentiated pleomorphic sarcoma; WDLPS, well-differentiated liposarcomaGene/ PathwayType of alterationSarcoma subtypes commonly affectedApprox. frequency(% of Cases)Functional/Clinical significanceKey references TP53 Missense / truncating mutations, deletionsUPS, LMS, osteosarcoma35–55%Central tumor suppressor; mutations linked to genomic instability and poor prognosisCote et al., [16], Dorand, [22], Nacev, [54] RB1 Deletions, LOF mutationsOsteosarcoma, UPS, LPS20–40%Cell cycle regulation; loss drives uncontrolled proliferationBajpai et al., [4], Gounder, [30]CDKN2A/ CDKN2BHomozygous deletions, promoter methylationSynovial sarcoma, UPS, EWS15–30%Loss of G1 checkpoint control; correlated with metastasisNacev et al., [54];Gounder et al., [30] MDM2 Gene amplificationLPS, intimal sarcoma65–90% in WDLPS/DDLPSInhibits TP53; diagnostic and targetable alterationGounder et al., [30]; [22] PIK3CA Activating missense mutationsUterine LMS, angiosarcoma10–20%Activates PI3K/AKT/mTOR signaling; potential for PI3K inhibitorsBajpai et al., [4], Hensley, [35] PTEN LOF mutations, deletionsLMS, osteosarcoma10–15%Tumor suppressor; loss increases mTOR signalingHensley et al., [35]; [54] ATRX Loss-of-function mutationsLMS, angiosarcoma15–25%Chromatin remodeling; associated with telomere maintenance (ALT phenotype)Hensley et al., [35]; [54]CDK4/ CCND1AmplificationsLPS, dedifferentiated sarcoma60–80%Drives cell cycle progression; predictive for CDK4 inhibitor responseBajpai et al., [4], Gounder, [30] NF1 Inactivating mutationsMPNST, UPS10–20%Ras pathway activation; loss promotes MAPK signalingDorand et al., [22], Nacev, [54]EWSR1-FLI1/ERGGene fusionEWS> 95%Diagnostic and oncogenic driver fusionRacanelli et al., [58], Zhu, [76]FUS-DDIT3Gene fusionMLPS~ 90%Defines subtype; transcriptional reprogrammingAggarwal et al., [1], Lam, [45]SYT-SSX1/2/4 (SS18-SSX)Gene fusionSynovial sarcoma> 90%Diagnostic hallmark; epigenetic transcriptional regulatorLam et al., [45]; [58]COL1A1-PDGFBGene fusionDFSP~ 95%Constitutive PDGFB signaling; imatinib-sensitiveHu et al., [37], Racanelli, [58]ALK/ROS1/ NTRK1-3Gene fusions, rearrangementsIMT, infantile fibrosarcoma, rare soft-tissue sarcomas5–10% overall; 70–90% in IMT or NTRK+ sarcomasOncogenic kinase fusions; highly druggableGounder et al., [30], Weiss, [71]TERT promoterMutations, rearrangementsOsteosarcoma, LMS10–20%Telomerase reactivation; confers immortalizationBhonde et al., [7], Nacev, [54]IDH1/IDH2Missense mutationsChondrosarcoma50–60% (IDH1/2 combined)Alters 2-hydroxyglutarate metabolism; IDH inhibitor targetDorand et al., [22], Gounder, [30]BRAF/NRAS/KRASActivating mutationsAngiosarcoma, epithelioid sarcoma5–15%MAPK pathway activation; potential target for MEK/BRAF inhibitorsDorand et al., [22], Nacev, [54]TSC1/TSC2Inactivating mutationsPEComa, LMS20–40% (esp. in PEComas)mTOR pathway activation; predictive of rapalog sensitivityBajpai et al., [4], Gounder, [30]FAT1/NOTCH1Mutations, truncationsUPS, LMS10–15%Disrupts cell adhesion and Wnt/Notch signalingBhonde et al., [7], Grachev, [29]BCOR/BCORL1Mutations, gene fusionsBCOR sarcomas, clear cell sarcoma of kidney50–80% in BCOR-rearranged tumorsDefines molecular subtype; transcriptional repression complexGrachev et al., [29]; [54]NAB2-STAT6Gene fusionSolitary fibrous tumor> 90%EGR1-dependent transcription activation; diagnostic driver fusionGeorgiesh et al., [26], Robinson, [63] MYOD1 Point mutation (most commonly p.L122R)Spindle cell/sclerosing RMS30–70%Oncogenic mutation, aggressive phenotype, transcriptional reprogrammingKohsaka et al., [44], Rekhi, [59] Most relevant mutations and genomic alterations identified by NGS in sarcomas. Abbreviations: DDLPS, dedifferentiated liposarcoma; DFSP, dermatofibrosarcoma protuberans; EWS, Ewing sarcoma; IMT, inflammatory myofibroblastic tumor; LMS, leiomyosarcoma; LOF, loss-of-function; LPS, liposarcoma; MLPS, myxoid liposarcoma; MPNST, malignant peripheral nerve sheath tumor; PEComa, perivascular epithelioid cell tumor; RMS, rhabdomyosarcoma; UPS, undifferentiated pleomorphic sarcoma; WDLPS, well-differentiated liposarcoma Nacev et al., [54]; Gounder et al., [30] Furthermore, longitudinal sequencing has revealed the dynamic nature of mutational events over time. Studies have shown that recurrent mutations may emerge under therapeutic pressure, emphasizing the adaptive capabilities of sarcomas and the importance of continued genomic monitoring [14]. Collectively, these findings demonstrate that NGS enables a more precise understanding of sarcoma genomics, fostering the identification of novel therapeutic targets and contributing to personalized treatment design. Importantly, mutation detection alone does not establish clinical actionability. Variant interpretation requires assessment of tumor purity, sequencing depth, germline versus somatic origin when relevant, functional evidence, drug availability, and the level of clinical evidence supporting a matched intervention, ideally according to standardized actionability and reporting frameworks such as ESCAT and ESMO genomic-reporting recommendations [30, 53, 54, 66]. Fusion Gene Identification Fusion gene identification is among the most important applications of NGS in sarcoma research and diagnostics (Table 2). Several sarcoma subtypes are defined by pathognomonic gene fusions, such as EWSR1-FLI1/EWSR1-ERG in Ewing sarcoma, SS18-SSX1/2/4 in synovial sarcoma, FUS-DDIT3 in MLPS, COL1A1-PDGFB in dermatofibrosarcoma protuberans, and NAB2-STAT6 in solitary fibrous tumor, PAX3-FOXO1 in alveolar RMS, which play pivotal roles in diagnosis, classification, and, in selected cases, therapeutic stratification [18, 58, 60, 69]. Traditional detection techniques such as FISH and RT-PCR remain valuable, rapid, and widely available tools, but they are limited when the fusion partner is unknown or when multiple diagnostic possibilities must be evaluated simultaneously. Table 2Most relevant fusion genes identified by NGS in sarcomas. Abbreviations: DFSP, dermatofibrosarcoma protuberans; EWS, Ewing sarcoma; IMT, inflammatory myofibroblastic tumor; LPS, liposarcoma; MLPS, myxoid liposarcoma; RMS, rhabdomyosarcoma; STS, soft tissue sarcomaFusion geneSarcoma subtype(s)Approx. frequencyFunctional / Clinical significanceKey references EWSR1–FLI1 / EWSR1–ERGEWS> 95%Pathognomonic; major diagnostic criterion; transcriptional reprogramming driverRacanelli et al., [58], Zhu, [76] SS18–SSX1/SSX2(SYT–SSX)Synovial sarcoma> 90%Defines subtype; chromatin remodeling; central oncogenic driverLam et al., [45], Racanelli, [58] FUS–DDIT3MLPS~ 90%Diagnostic hallmark; alters adipocytic differentiation; prognostic relevanceLam et al., [45]; [1] COL1A1–PDGFBDFSP~ 95%Constitutive PDGFB signaling; imatinib-sensitive targetable fusionHu et al., [37], Racanelli, [58] NTRK1/2/3 fusions(various partners)Infantile fibrosarcoma; rare STS70–90% in NTRK+ sarcomasOncogenic kinase activation; highly actionable with TRK inhibitorsGounder et al., [30], Weiss, [71] ALK rearrangements(e.g., TPM3–ALK)IMT50–60%Tyrosine kinase activation; ALK inhibitor–sensitiveWeiss et al., [71]; [30] ROS1 fusionsIMT; rare STS~ 10%Kinase activation; targetable with ROS1 inhibitorsWeiss et al., [71]; [30] BCOR–CCNB3 BCOR–rearranged sarcoma50–80%Defines a molecular subtype; transcriptional repression complex dysregulationGrachev et al., [29], Nacev, [54] PAX3-FOXO1 alveolar RMS60–70%primary molecular driverLinardic, [48] Most relevant fusion genes identified by NGS in sarcomas. Abbreviations: DFSP, dermatofibrosarcoma protuberans; EWS, Ewing sarcoma; IMT, inflammatory myofibroblastic tumor; LPS, liposarcoma; MLPS, myxoid liposarcoma; RMS, rhabdomyosarcoma; STS, soft tissue sarcoma EWSR1–FLI1 / EWSR1–ERG SS18–SSX1/SSX2 (SYT–SSX) NTRK1/2/3 fusions (various partners) ALK rearrangements (e.g., TPM3–ALK) NGS technologies, particularly RNA sequencing and anchored multiplex PCR, have revolutionized fusion gene discovery by enabling unbiased detection of known and novel fusion transcripts [13, 20, 45, 46]. Zhu et al., [76] successfully identified a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma using targeted RNA sequencing, showcasing NGS’s capability to detect cryptic fusion events. Similarly, Aggarwal et al., [1] validated RNA-based NGS panels that improved classification accuracy in soft-tissue sarcomas. In addition, genome-wide approaches and hybrid-capture NGS methods have proven effective in detecting structural rearrangements in formalin-fixed, paraffin-embedded (FFPE) samples [37]. The Italian ACC Sarcoma Working Group employed such methods to identify complex rearrangements across numerous subtypes [17, 58]. Beyond classification, fusion discovery through NGS has shed light on fusion-driven oncogenic mechanisms, revealing new potential therapeutic targets. Thus, RNA-based and targeted NGS approaches have become highly valuable tools for identifying gene fusions in sarcomas, particularly when histology and IHC do not establish a definitive diagnosis [47], when the expected fusion partner is unknown, or when broad molecular characterization is required. However, NGS should not be described as universally replacing FISH, RT-PCR, or IHC. Rather, its diagnostic and translational value depends on the clinical question, tissue quality, assay design, bioinformatic validation, and expert interpretation within multidisciplinary sarcoma and molecular tumor boards [53, 66, 69]. For known recurrent rearrangements in a well-defined clinicopathological context, FISH or RT-PCR may remain faster, cheaper, and sufficient; NGS adds most value when the differential diagnosis is broad, the fusion partner is unexpected, the sample is limited, or multiple alteration classes must be interrogated simultaneously [37, 45, 46, 58, 60, 69]. Tumor Heterogeneity and Evolution Sarcomas exhibit extensive heterogeneity both within individual tumors (intra-tumoral) and across patients (inter-tumoral), which contributes to variable treatment responses and disease progression. NGS has emerged as a critical tool for characterizing this heterogeneity and mapping clonal evolution over time [4, 15, 24]. Single-cell sequencing and multi-region sampling have provided unprecedented insight into the clonal composition of sarcomas. (Grachev et al., [29], [28]) used transcriptomic analyses to detect intra- and transchromosomal fusions that arise during tumor evolution, identifying specific clonal lineages associated with metastasis and therapy resistance. Eisenhardt et al., [24] applied circulating tumor DNA (ctDNA) genotyping to monitor synovial sarcoma dynamics, demonstrating how NGS can capture real-time tumor evolution and resistance mechanisms. Longitudinal sequencing of pediatric and adult sarcomas has revealed that mutations in TP53, MDM2, and ATRX often evolve under selective pressure from treatment, driving clonal diversification [14]. These findings highlight the adaptability of sarcoma genomes and underscore the need for integrative temporal profiling to optimize treatment strategies. In essence, NGS enables a multidimensional understanding of sarcoma heterogeneity—spanning genetic, spatial, and temporal dimensions—laying the groundwork for more dynamic therapeutic approaches. Biomarker and Target Discovery The discovery of predictive and prognostic biomarkers is a cornerstone of modern oncology, and NGS has accelerated this process in sarcoma research. By analyzing whole-exome or targeted sequencing data, researchers have identified molecular alterations that correlate with clinical outcomes and drug response [35, 49, 68]. Hensley et al., [35] used NGS to define the genomic landscape of uterine sarcomas, identifying actionable alterations in PIK3CA, PTEN, and ATRX. Similarly, Dufresne et al., [23] highlighted how biology-driven therapeutic selection can improve outcomes in aggressive sarcomas, emphasizing the potential of genomics-informed treatment. NGS also facilitates the identification of immune-related biomarkers. Studies using RNA-seq have characterized immune infiltration and tumor microenvironmental features that predict response to immunotherapy [24]. Moreover, computational interpretation of NGS data through machine learning approaches has allowed the discovery of non-obvious associations between gene expression signatures and therapeutic vulnerability [29]. In this regard, NGS has also revolutionized epigenomic research by enabling genome-wide DNA methylation profiling, complementing genomic and transcriptomic analyses. Whole-genome bisulfite sequencing (WGBS) and reduced representation bisulfite sequencing (RRBS) via NGS platforms reveal dynamic methylation patterns at CpG sites, uncovering sarcoma-specific epigenetic landscapes that drive heterogeneity and clonal evolution [6, 51]. NGS-based methylation studies highlight sarcoma subtypes’ distinct profiles: Ewing sarcoma exhibits hypomethylation at developmental enhancers, while synovial sarcoma shows hypermethylation of tumor suppressor promoters. Reduced representation bisulfite sequencing identifies differentially methylated regions (DMRs) linking methylation to fusion gene expression, such as SS18-SSX in synovial sarcomas, influencing chromatin accessibility. These patterns correlate with clonal dynamics, where methylation entropy tracks tumor evolution in leiomyosarcomas [10, 43, 51, 52 Integrating methylation arrays with NGS multi-omics reveals pan-sarcoma signatures; for instance, MethMarkerDB compiles 5.4 million DMRs from 658 WGBS datasets, pinpointing sarcoma-enriched loci for prognostic modeling. In undifferentiated sarcomas, methylation classifiers distinguish CIC/Bcor-altered entities from Ewing, aiding subtype deconvolution. Single-cell NGS epigenomics further dissects intratumor heterogeneity, exposing methylation gradients in mesenchymal progenitors [6, 52, 77]. Machine learning on NGS methylation data deciphers regulatory networks, predicting variant impacts on epigenomic states. Challenges include bisulfite conversion biases, addressed by long-read NGS for phase-resolved methylation. Future integration with spatial transcriptomics promises to map methylation in sarcoma microenvironments, advancing discovery research [10, 11, 38]. Assay Development and Validation In addition to discovery, NGS technologies have facilitated the development and validation of novel molecular assays. These assays enable sensitive, multiplexed detection of fusions, mutations, and other variants for both research and diagnostic use. Lam et al., [45] pioneered the use of anchored multiplex PCR–NGS for fusion detection, achieving superior sensitivity compared to conventional methods. Lanic et al., [46] extended this work by creating a ligation-dependent multiplex RT-PCR NGS assay capable of detecting diverse fusion events across sarcoma subtypes. Hu et al., [37] developed and validated an RNA sequencing panel optimized for FFPE samples, overcoming degradation issues common in archival tissue. Similarly, Jeyaraman et al., [40] designed custom gene panels for osteosarcoma and Ewing sarcoma, enabling focused mutation profiling and improving assay adaptability for low-quality samples. These efforts have enhanced assay reproducibility, sensitivity, and integration into diagnostic workflows. As NGS technologies continue to evolve, long-read sequencing and highly sensitive digital assays may improve analytical resolution and help address specific diagnostic questions in selected sarcoma settings, although their routine implementation requires technical validation and evidence of added clinical value [40, 56, 66]. Nevertheless, assay performance is strongly influenced by pre-analytical variables, nucleic-acid quality, panel design, fusion-calling algorithms, validation cohorts, and reporting standards. Therefore, diagnostic implementation requires orthogonal confirmation when appropriate and interpretation by molecular pathologists familiar with sarcoma-specific entities [37, 45, 46, 56, 66]. Multi-Omics Integration and Computational Approaches An emerging direction in modern sarcoma research is the integration of multi-omics data—combining genomic, transcriptomic, proteomic, and epigenomic information—to provide a holistic view of tumor biology and offer new opportunities for personalized medicine. However, the analysis and interpretation of high-throughput sequencing data pose significant challenges due to the high dimensionality, complexity, and heterogeneity [25, 42]. Computational methods leveraging statistical and machine learning (ML) approaches are becoming indispensable tools for addressing these challenges and further advancing precision oncology. An effort in this direction has been made by The Cancer Genome Atlas Research Network, which provided a comprehensive and integrated characterization of 206 adult soft tissue sarcomas based on a multi-platform genomic landscape [9]. Approaches for multi-omics data integration have been employed to identify mutational signatures, predict clinical outcomes [12], and monitor tumor dynamics [24]. These algorithms have proven particularly valuable for sarcoma classification and target identification [42, 65]. Moreover, the use of NGS-based approaches has led to a substantial reclassification of histopathological diagnoses, as reported in a recent study [55]. ML approaches are an emerging key component of such integrative approaches. ML models can learn complex patterns from high-dimensional multimodal data to predict various functional outcomes. The combined use of ML and NGS has facilitated the identification of novel prognostic and diagnostic biomarkers [64, 67] and improved the classification of distinct sarcoma subtypes [25]. Recently, a multi-algorithm ML framework identified a G protein–coupled receptor (GPR) signature with diagnostic and clinical relevance in soft tissue sarcomas [70]. In addition, first attempts have been made to derive ML models by combining biological and chemical data and predict candidate compounds for sarcoma treatment via drug repurposing [3] or activity predictions based on cell transcriptomic and compound data [72]. Thus, the integration of NGS with systems and chemical biology, encompassing both classical statistical approaches and ML models, adds a new dimension to research in complex cancer genomics. Translational Implications and Clinical Integration The translation of NGS discoveries into clinical practice marks one of the most promising but also most complex developments in sarcoma research [8] (Table 3). Clinical sequencing efforts, such as those reported by Gounder et al., [30], have demonstrated how genomic profiling can inform patient management by identifying actionable targets, supporting molecular classification, and guiding enrollment into precision-oncology trials. However, the clinical relevance of NGS findings varies substantially across sarcoma subtypes and should be interpreted in the context of validated biomarkers, available therapies, ESCAT levels of actionability, and clinical-trial access [53, 66]. Molecular tumor boards and sarcoma reference centers increasingly incorporate NGS results to recommend personalized treatment options, bridging the gap between research and clinical care [5]. Referral to expert centers is particularly important for rare sarcoma entities, diagnostically ambiguous tumors, suspected translocation-driven sarcomas, and advanced or refractory disease in which broad molecular profiling may identify tumor-agnostic biomarkers, actionable kinase fusions, or eligibility for molecularly matched trials. In routine practice, NGS should be integrated with morphology, IHC, FISH, RT-PCR [73], methylation profiling when appropriate, and clinical information rather than interpreted as an isolated result [17, 53, 66, 69]. Table 3Overview of NGS-Based Molecular Profiling Studies and Clinical Utility in Advanced Sarcomas. Abbreviations: GIST, gastrointestinal stromal tumor; NGS, next-generation sequencing; N/R, not reported. * The table reports the clinical benefits, defined as stable disease for more than 6 monthsStudyTumor typeNo. of samplesTumors with ≥ 1 genomic alteration% of patients with clinically actionable mutationsMost frequent alterationsPatients with NGS-influenced treatmentClinical benefit observed*Gusho et al., [33]Non-GIST sarcomas (116 soft tissue, 20 bone)13689.7%47.1% TP53, CDKN2A/B, RB1, CDKN2A123/12Boddu et al., [8]Non-GIST sarcomas (94 soft tissue, 20 bone)11496.7%49.1% TP53, CDKN2A/B, CDK4/MDM2, ATRX, RB1.154/15Groisberg et al., [31]Advanced sarcomas10293%N/R TP53, CDK4, MDM2, RB1, CDKN2A/B.168/16Gupta et al., [32]Advanced sarcomas108N/R24.4% N/R 164/16Jin et al., [41]Soft Tissue Sarcomas6595.4%36.9% TP53, MDM2, CDK4, EWSR1, KDR, NF1.42/4T Diab et al., [21]Non-GIST sarcomas (55 soft tissue, 23 bone)7887%42% CDK4, PIK3CA, NF1, ALK166/16 Overview of NGS-Based Molecular Profiling Studies and Clinical Utility in Advanced Sarcomas. Abbreviations: GIST, gastrointestinal stromal tumor; NGS, next-generation sequencing; N/R, not reported. * The table reports the clinical benefits, defined as stable disease for more than 6 months In practical terms, broad NGS is most informative in diagnostically challenging sarcomas, tumors with suspected but unconfirmed gene fusions, advanced or refractory disease, and rare entities in which molecular findings may refine classification or identify clinical-trial eligibility [73]. Examples include RNA-based fusion testing in Ewing sarcoma-like tumors, synovial sarcoma, MLPS, IMT, infantile fibrosarcoma and other NTRK-rearranged sarcomas, as well as targeted profiling for clinically relevant alterations when matched therapies or molecularly driven trials are available [30, 53, 55, 66, 69]. For example, patients harboring NTRK or ALK fusions identified by NGS have benefited from targeted kinase inhibitors, underscoring the tangible clinical value of genomic data [71]. NGS is a valuable tool for detecting mutations that can be targeted by emerging therapies, by identifying actionable alterations, molecular profiling can help expand therapeutic options and potentially improve survival outcomes [22] (Table 3). Although NGS-based molecular profiling may identify additional therapeutic opportunities with the potential to improve survival, available data in this clinical setting remain limited, with even fewer studies systematically evaluating the clinical utility of these approaches. Moreover, the predominantly retrospective design of the published studies and the frequent implementation of molecular profiling at advanced stages of disease represent important limitations that may restrict the clinical benefit of genomically guided therapeutic interventions. Moreover, liquid biopsy approaches leveraging ctDNA sequencing are enabling non-invasive tumor monitoring, capturing the genomic evolution of sarcomas in real time [24]. Liquid biopsy approaches based on ctDNA sequencing may provide a complementary strategy for non-invasive monitoring in selected sarcoma contexts, particularly when longitudinal tissue sampling is not feasible. However, their sensitivity varies by tumor burden, histotype, shedding rate, disease site, and assay design, and their routine use in sarcoma still requires further validation [14, 15, 24, 66]. Overall, the role of NGS in sarcoma research and selected clinical applications is expanding because it enables comprehensive genomic characterization, fusion discovery, investigation of tumor heterogeneity, biomarker and assay development. At the same time, technical, analytical, economic, and interpretive challenges remain, and the clinical impact of NGS depends on subtype-specific evidence, access to matched therapies, and multidisciplinary interpretation (Supplementary Table 1). Challenges and Future Directions Despite its transformative potential, several challenges limit the full realization of NGS in sarcoma research and practice. Technical issues such as degraded RNA in FFPE samples, low tumor purity, insufficient nucleic-acid input, and difficulty detecting low-frequency variants persist [56]. Bioinformatics complexity, including data storage, normalization, variant classification, fusion calling, and clinically meaningful reporting, continues to be a major bottleneck [39, 66]. These limitations should be considered alongside the strengths of established complementary methods: FISH and RT-PCR can be rapid and cost-effective for selected known rearrangements, IHC remains essential for lineage and surrogate marker assessment, and methylation classifiers may support diagnosis in selected ambiguous sarcomas. Additionally, the heterogeneity and rarity of sarcomas complicate statistical validation of genomic findings. Large-scale, multi-institutional collaborations are therefore essential to achieve sufficient cohort sizes for robust analysis. Initiatives such as the CCCLMU Molecular Tumor Board have demonstrated the success of collaborative genomic data sharing [5]. Future directions include integrating single-cell and spatial transcriptomics with NGS to uncover interactions between tumor cells and their microenvironment [4, 28] (Table 4). Combining genomics with proteomics, metabolomics, and functional models could also uncover dependencies that drive sarcoma growth and resistance. Ultimately, standardized computational pipelines, validated reporting frameworks, international data sharing, and open-access genomic repositories will be key to translating NGS data into reproducible biological and clinical insights [53, 66]. Table 4Future directions for advancing NGS research applications in sarcoma. Abbreviations: ML, machine learning; NGS, next-generation sequencingOpen questionsRelevance How can single-cell and spatial transcriptomics be integrated with NGS to better understand sarcoma heterogeneity? Integration could reveal new insights into tumor evolution, microenvironment, and resistance mechanisms. What are the most effective computational and machine learning approaches for analyzing complex NGS data in sarcoma research? Improved tools are needed to interpret large, multi-dimensional datasets and identify novel patterns. How can NGS-based research be expanded to cover rare and understudied sarcoma subtypes? Broader research will help uncover unique genetic drivers and inform future translational studies. Future directions for advancing NGS research applications in sarcoma. Abbreviations: ML, machine learning; NGS, next-generation sequencing Future efforts combining NGS-based biomarker discovery with innovative therapeutic platforms, including nanomedicine, may open new avenues for precision treatment in soft tissue sarcomas. However, these approaches remain largely preclinical and should be presented as emerging research directions rather than established clinical strategies. In this context, NGS-derived biomarkers may support the rational design of targeted drug-delivery systems [36], including nanoparticle-based platforms functionalized to recognize tumor-associated alterations or microenvironmental features, but such strategies require rigorous validation of target specificity, biodistribution, efficacy, and off-target toxicity before clinical translation. However, as reported by [75] the intrinsic heterogeneity of STSs poses significant challenges to the development of universally effective nanoparticle-based therapeutic strategies, highlighting the need for subtype-specific approaches [50]. Mutations and molecular vulnerabilities identified through omics analyses must be validated in appropriate preclinical models to elucidate their biological functions and their implications for therapeutic response. In vivo models remain important because they can capture tumor-host interactions, vascularization, immune components, and systemic pharmacology more effectively than simplified in vitro systems. The choice of model should be driven by the biological question, sarcoma subtype, genetic alteration, and intended translational endpoint [19, 34, 60–62]. Zebrafish models are highly amenable to genetic manipulation and can provide a rapid, cost-effective in vivo platform for investigating oncogenic mechanisms, developmental pathways, tumor dissemination, and drug response in sarcoma research. Their optical transparency, fecundity, and suitability for high-throughput screening represent important advantages, while evolutionary distance from humans, differences in immune maturation, and limitations in modeling some aspects of the mammalian tumor microenvironment should also be acknowledged ([34, 60] b, [27]). The partial genomic redundancy resulting from the teleost genome duplication can facilitate the study of genetic interactions and modifier genes through the generation of compound mutants. Recent genome-editing approaches, including optimized CRISPR-based methods and emerging prime-editing strategies, may further improve the precision of disease-specific zebrafish model development. Once validated, these models can complement murine, organoid, patient-derived xenograft, and cell-line systems as platforms for functional genomics and drug screening in rare sarcoma subtypes ([34, 60] b). Conclusions Next-generation sequencing has substantially advanced sarcoma research by enabling the detection of genomic and transcriptomic alterations that contribute to the biology, classification, and clinical investigation of these rare malignancies. Its major contributions include mutation and variant discovery, fusion detection, biomarker development, assay validation, and integration with multi-omics and computational approaches. Nevertheless, NGS should be considered a powerful complementary technology rather than an all-purpose replacement for histopathology, IHC, FISH, RT-PCR, or other established diagnostic methods. Future progress will depend on careful integration of NGS with single-cell sequencing, spatial transcriptomics, methylation profiling, functional models, artificial intelligence, and prospective clinical studies. For patients with sarcoma, the greatest impact is likely to occur when molecular data are generated using validated assays, interpreted by expert multidisciplinary teams, and linked to subtype-specific evidence, actionable biomarkers, and clinical-trial opportunities. A balanced implementation of NGS may therefore strengthen both biological discovery and precision oncology while avoiding overinterpretation of exploratory findings. Highlights the diagnostic value of broad RNA-based fusion detection for improving molecular classification of soft tissue sarcomas. Key Reference Aggarwal et al. (2025). RNA-based fusion NGS panel testing for the improved classification of soft tissue sarcomas.○ Highlights the diagnostic value of broad RNA-based fusion detection for improving molecular classification of soft tissue sarcomas. Aggarwal et al. (2025). RNA-based fusion NGS panel testing for the improved classification of soft tissue sarcomas.○ Highlights the diagnostic value of broad RNA-based fusion detection for improving molecular classification of soft tissue sarcomas. ○ Highlights the diagnostic value of broad RNA-based fusion detection for improving molecular classification of soft tissue sarcomas. ○ Highlights the diagnostic value of broad RNA-based fusion detection for improving molecular classification of soft tissue sarcomas. Miettinen et al. (2024). Assessment of the utility of the sarcoma DNA methylation classifier in surgical pathology.○ Supports the role of genome-wide methylation-based classifiers in diagnostically challenging sarcomas. Miettinen et al. (2024). Assessment of the utility of the sarcoma DNA methylation classifier in surgical pathology.○ Supports the role of genome-wide methylation-based classifiers in diagnostically challenging sarcomas. ○ Supports the role of genome-wide methylation-based classifiers in diagnostically challenging sarcomas. ○ Supports the role of genome-wide methylation-based classifiers in diagnostically challenging sarcomas. Gounder et al. (2022). Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma.○ Provides clinical genomic profiling data relevant to management and molecular stratification of sarcoma patients. Gounder et al. (2022). Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma.○ Provides clinical genomic profiling data relevant to management and molecular stratification of sarcoma patients. ○ Provides clinical genomic profiling data relevant to management and molecular stratification of sarcoma patients. ○ Provides clinical genomic profiling data relevant to management and molecular stratification of sarcoma patients. Wallander et al. (2023). Sarcoma care in the era of precision medicine.○ Provides a precision-medicine framework for integrating molecular diagnostics, prognostic markers, and therapeutic implications in sarcoma care. Wallander et al. (2023). Sarcoma care in the era of precision medicine.○ Provides a precision-medicine framework for integrating molecular diagnostics, prognostic markers, and therapeutic implications in sarcoma care. ○ Provides a precision-medicine framework for integrating molecular diagnostics, prognostic markers, and therapeutic implications in sarcoma care. ○ Provides a precision-medicine framework for integrating molecular diagnostics, prognostic markers, and therapeutic implications in sarcoma care. Mosele et al. (2024) and van de Haar et al. (2024). ESMO precision-medicine and genomic-reporting recommendations.○ Support cautious interpretation, standardized reporting, and clinically meaningful actionability assessment of NGS findings. Mosele et al. (2024) and van de Haar et al. (2024). ESMO precision-medicine and genomic-reporting recommendations.○ Support cautious interpretation, standardized reporting, and clinically meaningful actionability assessment of NGS findings. ○ Support cautious interpretation, standardized reporting, and clinically meaningful actionability assessment of NGS findings. ○ Support cautious interpretation, standardized reporting, and clinically meaningful actionability assessment of NGS findings. Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 1 (26.0 KB) Supplementary Material 2 (14.9 KB ) Acknowledgements This work was partly supported thanks to the contribution of Ricerca Corrente by the Italian Ministry of Health. Abbreviations dermatofibrosarcoma protuberans dedifferentiated liposarcoma differentially methylated region European Society for Medical Oncology ESMO Scale for Clinical Actionability of molecular Targets Ewing sarcoma formalin-fixed paraffin-embedded fluorescence in situ hybridization gastrointestinal stromal tumor G protein-coupled receptor inflammatory myofibroblastic tumor immunohistochemistry leiomyosarcoma loss-of-function liposarcoma machine learning malignant peripheral nerve sheath tumor next-generation sequencing perivascular epithelioid cell tumor rhabdomyosarcoma reduced representation bisulfite sequencing reverse-transcription polymerase chain reaction single-nucleotide variant soft tissue sarcoma undifferentiated pleomorphic sarcoma well-differentiated liposarcoma whole-genome bisulfite sequencing Author Contributions SVa and ADV designed and conceived the project. SVi, GM, EX and JB collaborated on data acquisition and analysis. SVi, SVa, ADV, EX and JB drafted the original article. All authors have read and agreed to the published version of the manuscript. Data Availability The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request. Declarations Ethical approval, consent to participate and consent for publications Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 (26.0 KB) Supplementary Material 2 (14.9 KB ) Data Availability Statement The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.